The Intelligent Retinal Imaging System (IRIS) http://retinalscreenings.com, a retinal screening solution is the first and only FDA Cleared Class II device for use as a telemedicine platform to screen patients for diabetic retinopathy, macular edema, glaucoma, and other suspected conditions.
Ingrid Zimmer-Galler, M.D. Associate Professor at Wilmer Eye Institute www.hopkinsmedicine.org/wilmer and board member of the American Telemedicine Association (ATA) www.americantelemed.org, said, “IRIS has delivered a major step forward in the global advancement of telemedicine technology. This is another validation of a system with the potential to significantly expand access for millions of patients with diabetes who fail to receive annual retinal assessments.”
The IRIS is a comprehensive web-based software system application intended for use in storing managing, and displaying patient data, diagnostic data, and images from computerized diagnostic instruments or systems. Original and color amplified images can be viewed by trained healthcare professionals.
“The recent FDA clearance underscores just how unique our service is,” said Jason Crawford, CEO for IRIS. “Healthcare providers and payers across the country seeking to improve their quality scores specifically for diabetic retinopathy can now rely on our team to guide them through the process.”